Replies to post #3704 on Rexahn Pharmaceuticals, Inc. (REXN)

[n3m3sis]

Not so.....

This is the entry on FDA Calendar

Archexin
Renal cell carcinoma (RCC) - cancer
Phase 2a
12/31/2017
Phase 2a second stage enrolment commenced February 2016. Noted May 4, 2017 an update due later this year

This is still a strong stock with 2 catalyst's due by 12/31/2017 and 1 "later this year" with 1 more in 2Q 2018. All upcoming catalysts are either Phase 2 or 2a

They may or may not have mis-calculated with the RS, however I still believe that RNN will come good. It has hit oversold territory and also seems to have found it's bottom. If the Archexin news is good, then it will rocket back up again, given that two of the other three catalysts are due by the end of 2017.


GO $RNN

[henery8th]

YA, WE SURE GOT TAKEN TO THE CLEANERS ON THAT DEAL ???????